THE GENECTION DIFFERENCE
In order to make personalized molecular medicine a clinical reality, new platforms need to be developed for the delivery of healthcare. Genection's mission seeks to accelerate the adoption process of making personalized molecular medicine a clinical reality by developing new platforms for the delivery of healthcare.
Introducing MyAML. A targeted NGS panel specifically designed with acute myelogenous leukemia in mind. Used to stratify patients in clinical trials, follow sub-clonal architecture longitudinal across clinical trials, and assist oncologists in determining the best care for their patients. With 194 genes, this panel will bring forth a whole new level in understanding leukemias.
The San Diego-based company will serve as the gateway to the Together We Cure, a global initiative aimed at developing treatments for acute myeloid leukemia.